Surviving the HIV Epidemic (S/HE) in metropolitan Washington DC - Advancing knowledge through cohort studies

在华盛顿特区大都市的艾滋病毒流行 (S/HE) 中生存 - 通过队列研究增进知识

• 批准号: 10222139
• 负责人: SEBLE G KASSAYE
• 金额: $ 5.66万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-01 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10222139
• 关键词: Address; Adolescent; Adult; Affect; Age; Aging; Anti-Retroviral Agents; Area; Behavioral; Behavioral Research; Biological Factors; Biological Markers; Blood Vessels; Capital; Cardiovascular Diseases; Chronic; Cohort Studies; Collaborations; Communities; Complex; Continuity of Patient Care; Death Rate; Diagnosis; Disease; Disease Outcome; District of Columbia; Dyslipidemias; Enrollment; Ensure; Epidemic; Failure; Funding; Geographic Factor; Geography; Goals; HIV; HIV Infections; Health; Health Personnel; Healthcare Systems; Hearing problem; Immunologics; Impairment; Individual; Intervention; Knowledge; Lead; Leadership; Life; Malignant Neoplasms; Maryland; Measures; Mediating; Mental disorders; Metabolic; Morbidity - disease rate; Neurocognitive Deficit; Newly Diagnosed; Outcome; Participant; Play; Population; Positioning Attribute; Prevalence; Prevention; Prevention Guidelines; Preventive screening; Protocols documentation; Research; Research Personnel; Risk; Risk Factors; Role; Savings; Science; Site; Socioeconomic Status; Surveys; The Multicenter AIDS Cohort Study; Translating; Treatment Effectiveness; Treatment Protocols; United States; Viral; Virus; Washington; Woman; Women’s Interagency HIV Study; aged; antiretroviral therapy; base; behavioral study; cardiovascular disorder risk; cardiovascular risk factor; cohort; comorbidity; coping; data acquisition; effective therapy; equilibration disorder; glucose metabolism; health seeking behavior; healthy aging; high risk; immune activation; improved; innovation; lifetime risk; male; men; men' s group; metropolitan; microbiome; mortality; novel; optimal treatments; outcome prediction; pre-clinical; prevent; protocol development; psychosocial; racial difference; recruit; research study; resilience; service delivery; side effect; social; social determinants; success; tool; transmission process; treatment adherence; treatment guidelines; uptake; virology

ABSTRACT About 1.1 million people are living with HIV (PLWH) in the US, with an estimated 39,782 individuals newly diagnosed with HIV in 2016. The Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) are two of the longest standing HIV cohort studies in the United States. Established in 1984 and 1993, respectively, these US-based cohorts currently follow 2,235 men and 2,304 women living with HIV, alongside high-risk but uninfected controls. HIV is at epidemic proportions in the nation’s capital, with overall HIV prevalence of 1.9% among the District of Columbia (DC) adult and adolescent residents. Approximately 3.7% of DC residents aged 40 to 49 years and 5.2% of residents aged 50 to 59 years are living with HIV. The highest life time risk of acquiring HIV in the U.S. is highest in DC with an estimated 1 in 17 individuals anticipated to acquire HIV in their lifetime, followed by 1 in 56 risk among the neighboring Maryland residents. Continuing to follow the women we have recruited and expanding our cohort to include a representative group of men and women is imperative in this region with epidemic levels of HIV. Our research will be focused on understanding the behavioral and social determinants that contribute to long term treatment success and failure, with a focus on identifying key resilience factors that may translate into innovative interventions to achieve the global goals of the HIV care continuum, to improve treatment uptake and viral suppression to decrease morbidity and mortality. We have four aims to achieve our goals. (1) To continue our strong collaborative relationship with the national MACS/WIHS CCS in protocol development, implementation, participant enrollment, retention, data acquisition, and sub-study participation; (2) To lead the CCS-wide effort to understand the psychosocial and behavioral determinants that contributes to treatment adherence, virologic suppression, and healthy coping among PLWH in the US; (3) To determine the effectiveness of treatment and prevention guidelines and identify disparities in service delivery for common morbidities with high associated mortality; and (4) To explore HIV, aging, and associated co-morbidities, including the role of microvascular/vascular function, the microbiome, neurocognitive decline in the context of contemporary antiretroviral treatment regimens, and hearing and balance disorders among men and women. Our long-term goal is to improve the health of people living with HIV and to help prevent those without HIV from seroconverting.

抽象的 在美国，约有110万人患有艾滋病毒（PLWH），估计有39,782个人 2016年被诊断出患有艾滋病毒。多中心艾滋病队列研究（MAC）和妇女的机构间艾滋病毒 研究（WIHS）是美国最长的艾滋病毒队列研究中的两个。成立于1984年， 1993年，这些总部位于美国的队列目前分别遵循2,235名男性和2,304名艾滋病毒的妇女， 与高风险但未感染的控件一起。艾滋病毒在美国首都处于流行状态，总体上 哥伦比亚特区（DC）成人和青少年居民的HIV患病率为1.9％。大约 在40至49岁的DC居民中，有3.7％的居民在50至59岁的居民中有5.2％的艾滋病毒居住。这 在美国获取艾滋病毒的终身时间风险最高，在DC中最高，估计有17个人中有1个 预计将在他们的一生中获取艾滋病毒，随后在邻近的马里兰州居民中有56种风险。 继续跟随我们招募的妇女，并扩大了我们的同伙，以包括代表团体 在该地区，男性和女性必须具有艾滋病毒的流行水平。我们的研究将集中于 了解有助于长期治疗成功的行为和社会决定者 失败，重点是确定可能转化为创新干预措施的关键弹性因素 实现艾滋病毒护理连续体的全球目标，以改善治疗摄取和病毒抑制 降低发病率和死亡率。我们有四个目标来实现我们的目标。 （1）继续我们的坚强 与国家Mac/WIHS CCS的协作关系在协议开发，实施中， 参与者入学，保留，数据获取和子研究参与； （2）领导CCS范围的努力 了解有助于治疗依从性，病毒学的社会心理和行为决定者 在美国的PLWH中的抑制和健康的应对； （3）确定治疗的有效性和 预防指南并确定服务提供的差异，以供高度关联的常见病态 死亡; （4）探索艾滋病毒，衰老和相关的合并症，包括 微血管/血管功能，微生物组，当代背景下的神经认知能力下降 抗逆转录病毒治疗方案，男性和女性的听力和平衡障碍。我们的长期 目标是改善艾滋病毒感染者的健康，并帮助防止没有艾滋病毒的人 血清换向。